louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05266547: Impact of OCT on Outcomes in AMI
Official title: Impact of Optical Coherence Tomography on Long-term Clincal Outcomes in Patients With Acute Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myocardial Infarction
Keywords: Tomography, Optical Coherence
STEMI
NSTEMI
Major adverse cardiovascular event
Lead sponsor: Beijing Luhe Hospital
Sponsor class: OTHER
First posted: 2022-03-04
Enrollment: 1600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: In this retrospective study, all the patients ≥18yesrs with AMI enrolled was devided into 2 groups, the primary endpoint will be major adverse cardiovascular events at least 3 years clinical follow up.

Brief summary: This protocol describes a retrospective, single-center study intended to test the impact of optical coherence tomography(OCT) on long term clincical outcomes in patients with acute myocardial infarction(AMI). All the patients will be followed by intracoronary OCT at medium follow-up of 3 years.


Eligibility criteria: Inclusion Criteria:

* Age≥18 years old
* Patients undergo cardiac catheterization and percutaneous coronary intervention(PCI) for AMI(STEMI or NSTEMI) ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction, symptoms onset≤ 24h.NSTEMI was defined as elevated troponin levels and the absence of ST elevation at the time of diagnosis, PCI was performed within 24hours after symtoms onset.
* Sufficient quality of the OCT recording allowing for CoreLab analysis.

Exclusion Criteria:

* ostial of Left main disease
* Cardiogenic shock or severe hemodynamic instability
* Severe renal insufficiency (creatinine clearance ≤30 mL/min)
* Bacteraemia or septicaemia
* Severe coagulation disorders
* Patients with life expectancy less than 1 year
* Patients who refuse to sign the informed consent form

Primary outcomes:
measure: major adverse cardiovascular event
timeFrame: 3 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Luhe Hospital
Study officials:
References:
Clinical trial NCT02211547: Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients
Official title: Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Levels of Pain
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: Children's Hospital Colorado
First posted: 2014-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary goal of the study is to determine if there is a difference in pain levels following the use of low level laser therapy versus placebo and control after placement of elastomeric orthodontic separators in pediatric patients. To test this, the investigators will assess the patient's pain levels immediately following separator placement and 24 hours post-operatively but having patients rate their pain on a 10 cm Visual Analog Scale (VAS). Patients will be randomly assigned to one of three groups: treatment, placebo, and control. The aim of this study is to establish whether or not low level laser therapy can be used to reduce pain in pediatric patients following separator placement.


Eligibility criteria: Inclusion Criteria:

* Absence of acute or chronic dental disease and periodontal disease
* Free from severe systemic disease
* No fixed orthodontic appliances currently placed
* No ankylosis or tooth implants within dentition
* No analgesic drug consumption for 48 hours preceding the study and during the study, a minimum age of 6 years

Exclusion Criteria:

* Presence of a diastema where the separator would be placed
* Conditions that could alter nociception, such as current or previous use of anti-inflammatory and analgesic drugs, antidepressants, anticonvulsants, and oral contraceptives
* Any medical conditions or medications that may contraindicate use of certain light/laser sources such as low level laser therapy (LLLT)

Primary outcomes:
measure: Pain experienced by the patient
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado, Pediatric Dental Center
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Linda Murzyn-Dantzer, DMD,MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01376947: Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous Women
Official title: Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous and Evaluation of Cause of Failure of Insertion
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Complication of Device Insertion
Keywords: IUD device insertion
Nulliparous
Multiparous
Pain
Lead sponsor: University of Campinas, Brazil
Sponsor class: OTHER
Collaborators: name: Center for Research on Reproductive Health of Campinas
First posted: 2011-06-20
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy women that desire to use IUD as anticonceptional method

Brief summary: In this study the investigators compare the difficulty at insertion of IUD between nulliparous and parous women. The investigators compare the pain reported by the patient to the difficulty reported by the professional that performed the insertion.

The investigators hypothesis is that there is no difference between nulliparous and multiparous patients.

Detailed description: In our study we compare the difficulty at insertion of IUD between nulliparous and parous women with an without cesarean section.

We compare the pain reported by the patient to the difficulty reported by the professional that performed the insertion. We also compare the pain the patient refers on the day of insertion and the pain the patient refers to remember a month after insertion.

Our hypothesis is that there is no difference between nulliparous and multiparous patients.

Eligibility criteria: Inclusion Criteria:

* Healthy WOmen

Exclusion Criteria:

* Pregnancy
* Use of pain medication previous to the insertion
* Prior use of IUDs

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Campinas
country: Brazil
facility: UNICAMP - Departamento de Tocoginecologia
state: SAo Paulo
Study officials:
affiliation: UNICAMP - master degree student
name: Ana Raquel Gouvea Santos, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Professor at UNICAMP
name: Ilza Urbano, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03237247: Role of Complete Blood Picture in Predicting the Etiology of Extrahepatic Cholestasis
Official title: Role of Complete Blood Picture in Predicting the Etiology of Extrahepatic Cholestasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Extrahepatic Cholestasis
Keywords: extrahepatic cholestasis, CBC
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-08-02
Enrollment: 38
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patients with extrahepatic cholestasis

Brief summary: Cases with extrahepatic cholestasis are common and faced during day to day clinical practice, however reaching the final etiology is sometimes challenging and needs investigations which are usually expensive, may carry hazards to the patients, or inaccessible so we are in need for a method which is easily available, affordable and safe for aiding in the differential diagnosis of extrahepatic cholestasis. our study aiming to evaluate the role of complete blood count in predicting the etiology of extrahepatic cholestasis.

Detailed description: Extrahepatic cholestasis has various etiologies including benign causes (benign stricture, chronic pancreatitis, choledochal cyst, mirizzi syndrome, etc...), choledocholithiasis, malignant causes (cancer pancreas, gallbladder cancer, cholangiocarcinoma, etc....), parasitic infestations (fasciola hepatica, ascaris lumbricoides, etc......) and other causes. it is essential to detect the exact cause of extrahepatic cholestasis in order to determine treatment options. diagnosing such conditions depends on clinical examination, laboratory investigations, imaging studies, endoscopic procedures, biopsy and even surgical intervention. some of these investigations are expensive, not available, or carry risk to the patients. moreover non of them is accurate 100%. Complete blood count is already available, easy to obtain, not invasive investigation. In these study we are trying to evaluate the role of complete blood count parameters namely RDW, MPV, PDW, PCT, NLR, PLR in the differential diagnosis of extrahepatic cholestasis.

Eligibility criteria: Inclusion Criteria:

* patients with extrahepatic cholestasis

Exclusion Criteria:

* age under 14 years
* previous bilio-pancreatic interventions
* hemoglobinopathy
* splenomegaly
* myeloproliferative disorders
* diabetes mellitus
* recent blood transfusion in less than one month

Primary outcomes:
measure: differential diagnosis of extrahepatic cholestasis
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01503645: Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism
Official title: Epidemiology of Chinese Herb Nephropathy and Its Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Kidney Diseases
Keywords: kidney diseases
drugs, Chinese herbal
aristolochic acid
polymorphism, genetic
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Department of Health, Executive Yuan, R.O.C. (Taiwan)
First posted: 2012-01-04
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: People who use Chinese herb

Brief summary: 1. Chinese herb nephropathy (CHN), a kind of kidney failure caused by Chinese herbs, may be related to the a component called aristolochic acid (AA).
2. AA may form AA-DNA adducts and accumulate in the kidney and ureter and cause kidney failure and/or cancer
3. Different enzymes have been reported to detoxify plant alkaloids or other components. Genes that regulate the production of these metabolic enzymes may affect the chance of CHN.
4. By comparing the differences in the polymorphisms of these genes between patient with CHN and control, we may find the changes that play a significant genetic factors for CHN.


Eligibility criteria: Inclusion Criteria:

* Patient with suspected Chinese herb nephropathy, and their family Control group match for sex age and geographic area (with or without herabla use)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pan-Chiao
country: Taiwan
facility: Far Estern Memorial Hospital
state: Taipei
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Kwan-Dun Wu, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01514045: The Gastric Cancer Foundation: A Gastric Cancer Registry
Official title: The Gastric Cancer Foundation: A Gastric Cancer Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Gastric Cancer
Keywords: Quality of Life
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2012-01-20
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be identified for recruitment either by the individual's treating physician or through information about the registry on the Gastric Cancer Fund website. Potential participants will be directed to the URL for the gastric cancer registry and asked to complete a brief registration form which will include eligibility questions.

Brief summary: The Gastric Cancer Registry will combine data acquired directly from patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene via an online questionnaire with genomic data obtained from saliva, blood and tissue samples. The purpose of this registry is to gain better understanding of the causes of gastric cancer, both environmental and genetic; whether certain genomic data can predict outcomes of treatment and survival.

Detailed description: Collect detailed clinical and epidemiological information on eligible patients via an online registry and a detailed patient questionnaire. Participants can opt in to contribute a blood or saliva sample and paraffin block samples from a previous gastric surgery.

Eligibility criteria: Inclusion Criteria:

1. Patients are eligible if they have a histologically proven gastric tumor including gastroesophageal tumors; OR they have a family history of gastric cancer in a first or second degree relative; OR persons with a known germline mutation in their CDH1 (E-Cadherin) gene.
2. 18 years of age or older
3. Adequate English proficiency to complete online consent and questionnaire. Spanish-language proficiency as an alternative to English-language proficiency.

Exclusion Criteria:

1. Under 18 years of age
2. No history of gastric cancer or gastric cancer in a family member or a known germline mutation in their CDH1 gene.

Primary outcomes:
measure: Collect detailed clinical and epidemiological information on patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University, School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Hanlee P Ji, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05896345: Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
Official title: Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone. A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Kidney Disease
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 76
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To conduct a RCT comparing SWL versus combined ODT and SWL as non-invasive methods for management of paediatrics radiolucent renal stone.


Eligibility criteria: Inclusion Criteria:

* 1-2.5 cm renal stone
* Normal Serum creatinine
* Radiolucent stone with Hounsfield units less than 400

Exclusion Criteria:

* Bleeding diatheses.
* Patients with a pacemaker.
* uncontrolled UTIs.
* Severe skeletal malformations.
* Arterial aneurysm in the vicinity of the stone.
* Anatomical obstruction distal to the stone.

Primary outcomes:
measure: Assess the stone free rate measured by computed tomograghy as asymptomatic insignificant residual fragments less than 3 mm
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Urology and Nephrology Center
state: Outside U.S./Canada
Study officials:
References:
Clinical trial NCT03709745: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Official title: A Randomized Trial Comparing Treatment with Aflibercept and Ranibizuamab for Macular Edema After Branch Retinal Vein Occlusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Branch Retinal Vein Occlusion with Macular Edema
Lead sponsor: St. Erik Eye Hospital
Sponsor class: OTHER
First posted: 2018-10-17
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

Detailed description: One hundred and ten patients with macular edema (ME) secondary to BRVO are randomized (1:1) to treatment with intravitreal injections of aflibercept or ranibizumab. An initial loading dose of at least three monthly injections is given in the study eye until the ME is resolved. Then patients are observed at regular intervals, initially every four weeks until study completion. Total follow-up time is nine months from baseline to completion. If ME recurs, patients are treated according to a treat-and-extend algorithm.

At every visit, visual acuity (VA) is measured with an ETDRS chart at 4 m. The fundus is examined by indirect ophthalmoscopy and by optical coherence tomography (OCT). Macular ischemia is evaluated with OCT angiography (OCT-A), visual field status with computerised perimetry and retinal sensitivity with microperimetry. Choroidal thickness is evaluated with enhanced depth imaging (EDI) OCT. Vision related quality of life (QoL) with NEI VFQ25.

Eligibility criteria: Inclusion Criteria:

* BRVO naïve patients, disease duration 1-6 months, BCVA 23-73 ETDRS letters (20/40-20/320), macula edema with intraretinal cysts and CRT \> 300 micrometers (Cirrus)

Exclusion Criteria:

* BRVO with neovascular component, intraocular surgery during the previous 3 months, earlier vitreoretinal surgery, vascular retinopathy of other cause, intraocular infection/inflammation, myocardial infarction och cerebrovascular stroke during the last 3 months.

Primary outcomes:
measure: Difference in time to recurrence of macular edema
timeFrame: 9 months
Secondary outcomes:
measure: Comparison of the number of patients without ME in each treatment arm at one month after the first injection
timeFrame: 1 month
measure: Comparison of the number of injections needed in each treatment arm to resolve ME
timeFrame: 9 months
measure: Correlation between choroidal thickness and recurrence of ME and with non response to the treatment drugs.
timeFrame: 9 months
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: St Eriks Eye Hospital
Study officials:
affiliation: St. Erik Eye Hospital
name: Anders Kvanta, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02607345: 25gr. Glucomedics vs 25gr. Zusto
Official title: 25gr. Glucomedics vs 25gr. Zusto
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: AZ-VUB
Sponsor class: OTHER
First posted: 2015-11-18
Enrollment: 10
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Objective: to compare blood glucose and insulin responses after consumption of 100ml water, sweetened with 25gr Zusto® and 100ml water sweetened with 25gr Glucomedics® (standard drink)

Detailed description: This is an experimental study enrolling 10 healthy female subjects. The study compares the blood glucose and insulin responses after consumption of 100ml water, sweetened with 25gr Zusto® and 100ml water sweetened with 25gr Glucomedics® (standard drink). Subjects need to be fasted for at least 8 hours before all visits. At visit 1, five women will consume the solution with 25gr Zusto®, the other five will have the solution with 25gr Glucomedics®. On visit 2, groups will be switched. Visit 1 and 2 will be performed within approximately one week interval.

Both drinks will be identical in amount of water and only be different by the use of 25gr Glucomedics® and 25gr Zusto®.

Before intake of the drink, vital signs, weight and bedside blood glucose and baseline blood samples - 15' and 0' for glucose, insulin and C-peptide will be taken at visit 1 and 2. Both drinks will be consumed within 5 minutes and time of start and end of intake of Zusto® / Glucomedics® will be documented.

Blood samples for glucose, insulin and C-peptide will be taken at 15', 30', 60', 90', 120' and 180' after start of intake 25gr Zusto® and 25gr Glucomedics®.

Eligibility criteria: Inclusion Criteria:

* Female subjects
* Age between 30 and 50 years
* BMI between 20 and 30 kg/m²

Exclusion Criteria:

* No first degree relatives with mellitus type 1 or type 2
* No intake of medication with influence blood glucose levels
* Pregnant, breast feeding or planning to become pregnant during the study
* Employer of the investigator or study center with direct involvement in the proposed study or other studies under the direction of the investigator or study center

Primary outcomes:
measure: the difference in glycemic index between 25gr. Zusto® and 25gr. Glucomedics®
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Universitair Ziekenhuis Brussel
name: Bart Keymeulen, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pen JJ, Khorosheva G, Van de Velde U, Debroye C, Huyghebaert A, Rottiers R, Keymeulen B. Zusto: A new sweetening agent with low glycemic index. Clin Nutr ESPEN. 2018 Feb;23:103-106. doi: 10.1016/j.clnesp.2017.11.009. Epub 2017 Dec 7.
Clinical trial NCT00726245: Plasma Rich in Growth Factors (PRGF) Treatment for Muscle Tear
Official title: PRP as a Treatment for Acute Muscle Tears - Randomized-double-blind-placebo Control Trail.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Muscle Tear
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2008-07-31
Enrollment: 50
Sex: ALL
Minimum age (years): 15
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the improvement of symptoms and disease progress by the treatment of OA of the knee with PRGF


Eligibility criteria: Inclusion Criteria:

* US diagnosed muscle tear
* age 15-40 years old

Exclusion Criteria:

* pregnancy
* mental or physical disabilities

Primary outcomes:
measure: improvement of symptoms / disease progress
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medicak Center
Study officials:
References: